AstraZeneca
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, AstraZeneca sits in the top decile of US sponsors by registered trial count (#20 of 15,742 sponsors by registered trial count).
AstraZeneca: 1,285 sponsored US clinical trials, 160 recruiting.
AstraZeneca sponsors 1,285 registered US clinical trials on ClinicalTrials.gov, 160 of them currently recruiting, and 883 completed. 484 of these trials are in Phase 3-4 (later-stage) and 720 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small Cell Lung Cancer, with 24 trials.
Top-decile sponsor footprint
AstraZeneca ranks in the top decile of sponsors by registered trial count (#20 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
883 of 987 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,285 total, page 25 of 26
To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)
NCT00658918
ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)
NCT00229684
Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects
NCT00444561
Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder
NCT00227305
Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
NCT00075959
GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin
NCT00242372
GALLANT 5 Tesaglitazar Versus Metformin
NCT00214591
GALLANT 6 Tesaglitazar vs. Pioglitazone
NCT00214565
AZD5438 in Patients With Advanced Solid Malignancies
NCT00088790
ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)
NCT00090363
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania
NCT00090311
Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00085891
NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis
NCT00206180
Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression
NCT00083954
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
NCT00093002
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.
NCT00206284
Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)
NCT00163514
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin
NCT00099320
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.
NCT00206245
Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
NCT00107731
Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
NCT00082277
Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer
NCT00502164
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer
NCT00075192
Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
NCT00081380
Iressa Versus Docetaxel (Taxotere)
NCT00076388
Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients
NCT00241501
Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents
NCT00099333
Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer
NCT00077025
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
NCT00076089
To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)
NCT00659841
LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes
NCT00214630
An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus
NCT01876849
The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)
NCT00076076
To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)
NCT00659750
Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)
NCT00163501
Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)
NCT00073177
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
NCT00206219
Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome
NCT00079833
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
NCT00229697
Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age
NCT00244634
Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age
NCT00244595
Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus
NCT00085969
A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
NCT00206102
Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
NCT00065117
CP-675,206 In Patients With Advanced Melanoma
NCT00086489
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
NCT00065325
Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes
NCT00064714
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
NCT00055471
Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
NCT00082381
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
NCT00062582
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 444 |
| Phase 2 | 276 |
| Phase 3 | 437 |
| Phase 4 | 47 |
Therapeutic Areas
What is open in the AstraZeneca pipeline
160 recruiting of 1,285 indexed (12% open); 883 completed (69%).
Phase mix: 484 late (III/IV) vs 720 early (I/II) (balanced across stages).
Top condition: Non-Small Cell Lung Cancer (24 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
AstraZeneca: open-pipeline peers nationwide
Peers matched on 1,285 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
AstraZeneca sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,285 trials (± recruiting share)
- University of Colorado, Denver · 1,283 trials · 21% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- University of Pittsburgh · 1,238 trials · 13% recruiting
- Eli Lilly and Company · 1,341 trials · 9% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Boston University · 12% recruiting · 185 trials
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
Related
What to do with this AstraZeneca page
1,285 registered trials is a research-attention snapshot, not an endorsement of AstraZeneca or any single study.
- 160 of AstraZeneca's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-Small Cell Lung Cancer is the condition AstraZeneca studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small Cell Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. AstraZeneca pipeline card: 1,285 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.